Patients' demographics and medical history
MSIG (n=12) | CG1 (n=10) | P value | CG2 (n=25) | P value | |
Male sex; n (%) | 6 (50.0) | 4 (40.0) | 0.970* | 10 (40.0) | 1.000* |
Age; median (range) | 75 (65–86) | 79 (61–87) | 0.469† | 79 (60–90) | 0.831† |
Arterial hypertension; n (%) | 11 (91.7) | 9 (90.0) | 1.000* | 23 (92.0) | 1.000* |
Diabetes mellitus; n (%) | 5 (41.7) | 3 (30.0) | 1.000* | 2 (8.0) | 0.051* |
Hyperlipidemia; n (%) | 5 (41.7) | 4 (40.0) | 1.000* | 11 (44.0) | 1.000* |
Body mass index; median (IQR) | 31.4 (26.3–36.4) | 25.1 (20.8–34.0) | 0.009† | 27.0 (23.9–37.0) | 0.017† |
Stroke or TIA; n (%) | 2 (16.7) | 2 (20.0) | 1.000* | 5 (20.0) | 1.000* |
Coronary heart disease; n (%) | 4 (33.3) | 3 (30.0) | 1.000* | 9 (36.0) | 1.000* |
Atrial fibrillation; n (%) | 7 (58.3) | 6 (60.0) | 1.000* | 11 (44.0) | 0.990* |
Smoking; n (%) | 1 (8.3) | 3 (30.0) | 0.589* | 3 (12.0) | 1.000* |
Alcohol abuse; n (%) | 0 (0.0) | 0 (0.0) | 1.000* | 0 (0.0) | 1.000* |
Antithrombotics at admission; n (%) | 7 (58.3) | 8 (80.0) | 0.762* | 12 (48.0) | 1.000* |
Antiplatelets; n (%) | 1 (8.3) | 6 (60.0) | 0.040* | 9 (36.0) | 0.238* |
Anticoagulants; n (%) | 6 (50.0) | 2 (20.0) | 0.408* | 3 (12.0) | 0.072* |
Statins at admission; n (%) | 4 (33.3) | 3 (30.0) | 1.000* | 11 (44.0) | 1.000* |
Glycemia level at admission; median (IQR) | 7.6 (5.1–11.4) | 6.4 (5.5–11.3) | 0.510† | 7.3 (5.0–15.9) | 1.000† |
Cholesterol level at admission; median (IQR) | 4.6 (3.0–5.6) | 4.0 (3.4–5.6) | 1.000† | 4.1 (3.2–5.6) | 1.000† |
Systolic blood pressure at admission; median (IQR) | 150 (110–200) | 145 (116–210) | 1.000† | 150 (100–210) | 1.000† |
Diastolic blood pressure at admission; median (IQR) | 80 (70–120) | 80 (70–115) | 0.941† | 80 (55–110) | 0.865† |
*Fisher’s exact test;
†Mann-Whitney U-test;
CG1, control group in center 1; CG2, control group in center 2; MSIG, microsurgical intervention group; TIA, transient ischemic attack.